Sarepta Therapeutics Inc (SRPT)

Currency in USD
18.18
+0.08(+0.44%)
Closed·
18.21+0.03(+0.19%)
·

SRPT Earnings

Latest Release
Aug 05, 2026
EPS / Forecast
0.64 / 0.22
Revenue / Forecast
401.3M / 383M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
2026/09--/0.222--/358.24M----Free Sign Up
2026/060.640/0.220401.30M/383.00M+190.91%+4.78%Free Sign Up
2026/033.16/0.990730.80M/474.26M+219.19%+54.09%Free Sign Up
2025/12-3.58/-1.21442.90M/379.71M-195.87%+16.64%Free Sign Up
2025/09-0.130/-0.700399.40M/337.91M+81.43%+18.2%Free Sign Up
2025/061.89/0.700611.09M/532.86M+170%+14.68%Free Sign Up
2025/03-4.60/1.96744.86M/695.90M-334.69%+7.04%Free Sign Up
2024/121.90/1.54658.40M/589.45M+23.38%+11.7%Free Sign Up
2024/090.620/-0.060467.20M/407.73M+1,133.33%+14.59%Free Sign Up
2024/060.440/-0.130362.90M/394.39M+438.46%-7.98%Free Sign Up

All numbers in USD

Sarepta Therapeutics Inc Earnings Call Summary for Q2/2026

  • Sarepta Q2 2026 EPS of $0.64 beat estimates by 191%, though revenue fell 34% YoY to $401.3M on weak ELEVIDYS gene therapy demand.
  • Company narrowed 2026 product revenue guidance to $1.2B-$1.3B from $1.2B-$1.4B; expects Q3 ELEVIDYS sales below Q2 levels.
  • Non-GAAP operating expenses cut sharply to $800M-$850M range; collaboration revenue raised $75M on higher Roche manufacturing income.
  • Cash position strengthened to $945M, up $197M sequentially; management cites improved ELEVIDYS enrollment trends despite revenue lag.
  • Shares rose 2.76% after hours to $16.37 following earnings beat; cohort 8 sirolimus data expected Q1 2027 amid ongoing regulatory reviews.
Last Updated: 2026-08-05, 06:10 p/m
Read Full Transcript

FAQ

What Is Sarepta's Earnings Per Share (TTM)?

The Sarepta EPS (TTM) is -1.32.

When Is The Next Sarepta Earnings Date?

Sarepta will release its next earnings report on Nov 04, 2026.

What Is Sarepta’s Revenue Forecasts For Upcoming Quarters?

Sarepta’s revenue forecast is 358.24M.

How Did Sarepta React to the Company's Latest Earnings Report?

Sarepta reported a +190.91% EPS surprise and a +4.78% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by 2.38%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.